Navigation Links
USF receives patent for technology to improve treatment for neurodegenerative diseases
Date:7/8/2010

Tampa, FL (July 8, 2010) The University of South Florida's Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood (HUCB) cells and a sugar-alcohol compound called "mannitol" that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke, among others.

The technology administers the neuroprotective effect of umbilical cord blood cells along with mannitol to permeabilize the blood-brain barrier, allowing for the increased entry of therapeutic growth factors. Saneron CCEL Therapeutics, Inc., a biotechnology R&D USF spin-out company located at the Tampa Bay Technology Incubator, has licensed the technology.

"Approximately 750,000 strokes occur every year in the United States, and nearly one third of them are fatal," said Saneron's President and COO, Nicole Kuzmin-Nichols, MBA. "Given the devastating effects of stroke, it is imperative that we develop new therapies to minimize damage to the brain as well as repair the damage. We are excited about this new technology and its potential to help us develop a variety of new products and therapies to do just that."

While transplanted HUCB cells may benefit several neurological diseases, getting them past the blood-brain-barrier has presented a problem. The blood-brain barrier separates circulating blood and cerebral spinal fluid in the central nervous system. The newly patented technology is based on mannitol acting as a blood-brain barrier permeabilizer to help get the therapeutic substances secreted by HUCB cells past the blood-brain barrier and into the central nervous system. Mannitol, which temporarily shrinks the tight cells that make up the barrier, allows HUCB cells, via their secreted factors, to reach the site of injury or disease.

"Human umbilical cord blood contains a high percentage of stem cells that when intravenously administered can survive and differentiate into neurons in the damaged brain. Equally appealing is their ability to secrete beneficial molecules that potentially promote behavioral recovery," said Dr. Cesar Borlongan, co-inventor and a USF neuroscientist and professor and consultant for Saneron. "Because the blood-brain barrier regulates the entry of many blood-borne substances into the brain, it may exclude potentially therapeutic substances."

"The use of stem cell therapy as a treatment for neurodegenerative disorders shows exciting promise, though several hurdles must be overcome and getting the cells correctly positioned is one of those," said Nicole Kuzmin-Nichols. "This technology provides the means to deliver the HUCB cells directly to the damaged brain to maximize their effect."


'/>"/>

Contact: Randolph Fillmore
rfillmor@health.usf.edu
813-974-0868
University of South Florida (USF Health)
Source:Eurekalert

Related medicine news :

1. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
2. Childrens Hospital Los Angeles oncologist receives $50,000 Hyundai Scholar Award
3. Stamen Medical Systems Receives Medicare Re-Accreditation and The Exemplary Provider Award
4. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
5. Datatel's Hosted Pay-by-Phone Credit Card Payment IVR Gateway Receives Heartland Payment Systems Certification
6. UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital
7. A*STAR scientist receives international award for innovation in healthcare technology
8. NYUs Movshon receives Champalimaud Vision Award for work on how brain reconstructs images
9. Sung-Cheng (Henry) Huang receives 2010 Benedict Cassen Prize for Research in Nuclear Medicine
10. Chester A. Mathis receives SNMs 2010 Aebersold Award
11. Bengt Roland Långström receives SNMs 2010 Georg Charles de Hevesy Nuclear Pioneer Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... Announced that Clear Global ... services market) has entered into an agreement on September 1, 2017 with The ... is the first private Dental School to launch an online, accredited Post Graduate ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gather for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New ... It is also when Athletic Trainers are acknowledged by their peers with accolades ...
(Date:9/20/2017)... ... 2017 , ... Five consumer packaged goods (CPG) products were selected by the ... Nopavera Plus was named to the short list in the Specialty Supplements ... during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort ...
(Date:9/20/2017)... Eugene, OR (PRWEB) , ... September 20, 2017 , ... ... OSHA 10- and 30-Hour and HAZWOPER 8-, 24- and 40-Hour courses from now until ... , In addition to offering these discounted prices to all businesses and government ...
(Date:9/20/2017)... ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A Bible-inspired ... the creation of published author, Bill Miller. Bill Miller has a unique ... than a decade of addiction to prescription drugs. He has a Bachelor ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology: